Loading...
XASX
SNT
Market cap9mUSD
Jan 02, Last price  
0.02AUD
Name

Pharmaxis Ltd

Chart & performance

D1W1MN
XASX:SNT chart
P/E
—
P/S
2.38
EPS
—
Div yield, %
—
Shrs. gr., 5y
11.98%
Rev. gr., 5y
-4.56%
Revenues
6m
-22.37%
05008,0002,357,000527,0001,025,0001,170,0001,202,0001,466,0003,237,0005,036,00057,741,00014,335,00013,286,0007,282,0005,676,0007,027,0006,680,0007,426,0005,765,000
Net income
-11m
L+486.78%
-6,000,669-10,232,357-17,733,000-24,179,000-20,440,000-35,171,000-46,345,000-45,758,000-38,644,000-43,537,000-51,818,00018,466,000-16,463,000-18,346,0006,428,000-20,058,000-13,943,000-2,970,000-1,936,000-11,360,000
CFO
-7m
L-55.36%
-4,652,150-9,274,214-13,775,000-20,697,000-18,850,000-26,469,000-39,683,000-37,366,000-38,142,000-35,383,000-28,132,00021,780,000-11,989,000-15,262,00012,206,000-19,798,000-13,284,0003,072,000-16,303,000-7,277,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Pharmaxis Ltd, an Australian biopharmaceutical company established in 1998 and headquartered in Frenchs Forest, specializes in the global research, development, and commercialization of therapeutic products for fibrotic and inflammatory diseases. Its business is organized into two main divisions: the Mannitol Respiratory Business and New Drug Development. The company currently markets Bronchitol, an inhaled dry powder medication for the treatment of cystic fibrosis, and Aridol, a diagnostic tool used to detect hyper-responsive airways and assist in the diagnosis and management of asthma. Pharmaxis also has a robust development pipeline featuring several investigational therapies. These include oral pan-lysyl oxidase (LOX) inhibitors aimed at myelofibrosis and various cancers; topical pan-LOX inhibitors designed to minimize skin scarring after events such as accidents, surgery, or burns; selective Lysyl Oxidase Like Inhibitors (LOXL2) targeting chronic fibrotic conditions like kidney, pulmonary, liver, and cardiac fibrosis; and compounds focused on neuroinflammatory diseases via semicarbazide-sensitive amine oxidase. Furthermore, the company is developing Orbital, a dry powder inhaler intended for the efficient delivery of high drug doses to the lungs.

Key people

Malcolm John McComas
Non-Executive Independent Chairman of the Board · since 2012
David Morris McGarvey
Chief Financial Officer, Company Secretary · since 2002
Gary Jonathan Phillips
Chief Executive Officer, Managing Director, Executive Director · since 2013
Brett Charlton
Medical Director · since 2006
Wolfgang G. Jarolimek
Head - Drug Discovery · since 2012
Kristen Morgan
Alliance Management and Medical and Regulatory Affairs · since 2015
William L. Delaat
Non-Executive Independent Director · since 2008
Kathleen Mary Metters
Non-Executive Independent Director · since 2017
URL
https://www.pharmaxis.com.au/
IPO date
Nov 10, 2003
Employees
69
Domiciled in
AU
Incorporated in
AU
Legal address
20 Rodborough Road
Frenchs Forest, NSW 2086
AU
Headquarters
Locked Bag 5015
Frenchs Forest, NSW 2086
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT